Resveratrol and Cardiac Fibrosis Prevention and Treatment

(E-pub Ahead of Print)

Author(s): Parinaz Zivarpour, Željko Reiner, Jamal Hallajzadeh*, Liaosadat Mirsafaei

Journal Name: Current Pharmaceutical Biotechnology

Become EABM
Become Reviewer
Call for Editor


Cardiovascular diseases are some of the major causes of morbidity and mortality in developed or developing countries but in developed countries as well. Cardiac fibrosis is one of the most often pathological changes of heart tissues. It occurs as a result of extracellular matrix proteins accumulation at myocardia. Cardiac fibrosis results in impaired cardiac systolic and diastolic functions and is associated with other effects. Therapies with medicines have not been sufficiently successful in treating chronic diseases such as CVD. Therefore, the interest for therapeutic potential of natural compounds and medicinal plants has increased. Plants such as grapes, berries and peanuts contain a polyphenolic compound called "resveratrol" which has been reported to have various therapeutic properties for a variety of diseases. Studies on laboratory models that show that resveratrol has beneficial effects on cardiovascular diseases including myocardial infarction, high blood pressure cardiomyopathy, thrombosis, cardiac fibrosis, and atherosclerosis. In vitro animal models using resveratrol indicated protective effects on the heart by neutralizing reactive oxygen species, preventing inflammation, increasing neoangiogenesis, dilating blood vessels, suppressing apoptosis and delaying atherosclerosis. In this review, we are presenting experimental and clinical results of studies concerning resveratrol effects on cardiac fibrosis as a CVD outcome in humans.

Keywords: Cardiovascular disease, cardiomyopathy, cardiac fibrosis, resveratrol, cardiovascular remodeling

Rights & PermissionsPrintExport Cite as

Article Details

Published on: 12 February, 2021
(E-pub Ahead of Print)
DOI: 10.2174/1389201022666210212125003
Price: $95

Article Metrics

PDF: 287